Entrada Therapeutics, Inc. (TRDA) stock

TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30

$5.17−0.27 (-4.96%)

Close on Nov 12, 2026Market cap $201.30MP/E –Yield –

Entrada Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Entrada Therapeutics's EV/EBITDA was 0.6× on Feb 28, 2025.

Period	Period end	Value	Change (pts)
2025	Feb 28, 2025	0.6×	−2.8
2024	Dec 31, 2024	3.4×	–

Parsed from the XBRL in Entrada Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is TRDA.

Revenue growth-93.5% · median 10.5%

Operating margin-4303.8% · median -726.5%

Net margin-4058.0% · median -1185.1%

Advertisement
300 × 250

See a number that looks wrong?